Nicotinamide mononucleotide (NMN) inhibits hepatocellular carcinoma progression by increasing NAD+ levels, enhancing apoptosis, autophagy, and ferroptosis, and activating the AMPK/mTOR pathway, suggesting its potential as a therapeutic agent for HCC. Here, MTOR is linked to hepatocellular carcinoma.